Regulatory Roundup: USP Announces Two Collaborations.

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeia (USP) has announced two new collaborations.

The US Pharmacopeia (USP) has announced two new collaborations. One involves working with the Republican State Enterprise National Center for Expertise of Drugs, Medical Products and Equipment of the Ministry of Health of the Republic of Kazakhstan to share standards for the quality, purity, strength, and identity of medicines. Specifically, the Kazahkhstan center will have a five-year renewable right to include written standards from the USP–National Formulary. Second, USP is joining with six government drug-control laboratories in the Middle East and North Africa to improve their capabilities to test the quality of drugs. Government agencies signing onto the network include: UAE: Health Authority of Abu Dhabi; Egypt: National Organization for Drug Control  Research; Jordan: Drug Quality Control Laboratory, Jordan Food and Drug Administration; Morocco: Direction de Médicament Et de la Pharmacie; Saudi Arabia: Products Evaluation and Standards-setting and National Drug and Cosmetic Control Laboratories (NDCCL) in Drug Sector, Saudi Food and Drug Authority; and Tunisia: Laboratoire National de Controle des Medicaments.

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content